Business
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common
About this update from Trevi Therapeutics, Inc.
[{"type":"image","alt":"Trevi Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Trevi Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":178,"url":"https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bm0hDKDh2VccPo04yMe8oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0OQ--/https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2","width":300,"height":178}},"lazy":false},{"type":"text","content":"NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total proceeds of the public offering were approximately $173 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering were sold by Trevi.","length":1025,"tagName":"p"},{"type":"text","content":"Morgan Stanley, Leerink Partners, Cantor, and Stifel acted as joint book-running managers for the offering and Oppenheimer & Co. acted as lead manager.","length":155,"tagName":"p"},{"type":"text","content":"The shares were offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-291517), which was filed with the Securities and Exchange Commission (SEC) on November 13, 2025 and became effective automatically upon filing. This offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering are disclosed in a final prospectus supplement which has been filed with the SEC. Copies of the final prospectus supplement...